FDA DTC Ad Study: Firms Win Small Concession; Viewings Will Be Less Dense
This article was originally published in The Pink Sheet Daily
Executive Summary
AbbVie, Valeant and Lilly had critiqued proposed study to assess impact of repeated exposure to direct-to-consumer drug ads on perception of risks and benefits.
You may also be interested in...
Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products
Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.
FDA’s Biggest DTC Advertising Study Eyes Online Promotion
The agency has 11 research projects under way, including a $2 million study of online Rx drug promotion; pharma spending on direct-to-consumer advertising declined in 2012 with biggest spends on Cymbalta and Cialis ads.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.